Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: The Austrian Hospital Screening Project (HSP);Lipidprofil und therapiestatus in der sekundärprävention bei hochrisiko-patienten mit klinisch manifester arteriosklerose und/oder diabetes mellitus: Das Hospital Screening Projekt (HSP) in Österreich

Wiener Klinische Wochenschrift

Volumn 120, Issue 17-18, 2008, Pages 558-565

  Roden, Michael ^a   Huber, Kurt ^b  

^a HANUSCH HOSPITAL   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Atherosclerosis; Cholesterol; Diabetes mellitus; HMG CoA reductase inhibitors statins; Hyperlipidemia; LDL C

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; AUSTRIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SECONDARY PREVENTION; SEX RATIO; TREATMENT OUTCOME;

AGED; AUSTRIA; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; INCIDENCE; MALE; MASS SCREENING; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION;

EID: 56249142341     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-008-1010-9     Document Type: Article

References (29)

1. I Graham D Atar K Borch-Johnsen G Boysen G Burell R Cifkova on behalf of the Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice 2007 European guidelines on cardiovascular disease prevention in clinical practice: executive summary Eur J Cardiovasc Prevention and Rehabilitation 14 Suppl 2 E1 E40
2. British Heart Foundation (2005) European cardiovascular disease statistics. British Heart Foundation, London
3. AJ Scheen H Kulbertus 2004 Interheart: nine risk factors predict nine out of ten myocardial infarctions Rev Med Liege 59 676 679
4. National Cholesterol Education Program Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panul III) 2002 Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and, treatment of high blood cholesterol in adults (Adult Treatment Panul III): final report Circulation 106 3143 3421
5. CP Cannon E Braunwald CH McCabe DJ Rader JL Rouleau R Belder 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 1495 1504
6. JC LaRosa SM Grundy DD Waters C Shear P Barter JC Fruchart Treating to New Targets (TNT) Investigators 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425 1435
7. SE Nissen EM Tuzcu P Schoenhagen BG Brown P Ganz RA Vogel 2004 Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 1071 1080
8. SE Nissen SJ Nicholls I Sipahi P Libby JS Raichlen CM Ballantyne 2006 Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial JAMA 295 1556 1565
9. Cholesterol Treatment Trialists' (CTT) Collaborators 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins Lancet 366 1267 1278
10. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake on behalf of the National Heart, Lung, and Blood Institute American College of Cardiology Foundation American Heart Association 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 239
11. [No authors listed] (2007) Diabetes mellitus - guidelines for general practice. Revised and expanded 2007 edition. Wien Klin Wochenschr 119/15-16 [Suppl 2]: 5-64
12. L Ryden E Standl M Bartnik G Van den Berghe J Betteridge MJ de Boer on behalf of the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) European Association for the Study of Diabetes (EASD) 2007 Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary Eur Heart J 28 88 136
13. K Pyorala TR Pedersen J Kjekshus O Faergeman AG Olsson G Thorgeirsson 1997 Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 614 620
14. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group 1998 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1349 1357
15. West of Scotland Coronary Prevention Study Group 1998 Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation 97 1440 1445
16. Heart Protection Study Collaborative Group 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 7 22
17. M Tonelli L Moye FM Sacks T Cole GC Curhan on behalf of the Cholesterol and Recurrent Events (CARE) Trial Investigators 2003 Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Ann Intern Med 138 98 104
18. PH Jones MH Davidson EA Stein HE Bays JM McKenney E Miller 2003 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 92 152 160
19. JM McKenney PH Jones MA Adamczyk VA Cain BS Bryzinski JW Blasetto 2003 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial Curr Med Res Opin 19 689 698
20. ES Ford AH Mokdad WH Giles GA Mensah 2003 Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults. Findings from the National Health and Nutrition Examination Survey, 1999 to 2000 Circulation 107 2185 2189
21. TA Pearson I Laurora H Chu S Kafonek 2000 The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 459 467
22. JP Frolkis GL Pearce V Nambi S Minor DL Sprecher 2002 Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice Am J Med 113 625 629
23. EUROASPIRE I & II Group European Action on Secondary Prevention by Intervention to Reduce Events 2001 Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries Lancet 357 995 1001
24. DT Ko M Mamdani DA Alter 2004 Lipid-lowering therapy with statins in high-risk elderly patients. The treatment-risk paradox JAMA 291 1864 1870
25. FA McAlister FME Lawson KK Teo PW Armstrong 2001 Randomised trials of secondary prevention programmes in coronary heart disease: systematic review Br Med J 323 957 962
26. LA Simons G Levis J Simons 1996 Apparent discontinuation rates inpatients prescribed lipid-lowering drugs Med J Aust 164 208 211
27. AS Brown RG Bakker-Arkema L Yellen RW Henley Jr R Guthrie CF Campbell 1998 Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin J Am Coll Cardiol 32 665 672
28. P Deedwania P Barter R Carmena JC Fruchart SM Grundy S Haffner on behalf of the Treating to New Targets Investigators 2006 Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study Lancet 368 919 928
29. TR Pedersen O Faergeman JJ Kastelein 2005 High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2437 2445